MedTrace Logo

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

NCT01450306 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-03-15

Study results available
· View outcomes & findings →

Summary

The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

Conditions

  • Specific Phobia

Interventions

DRUG

D-cycloserine

50 mg d-cycloserine, oral, 1 dose

BEHAVIORAL

Exposure therapy

Single session graded in vivo exposure therapy, 60-180 minutes

DRUG

Placebo

Single capsule of oral placebo, administered once 1 hr prior to exposure therapy

Sponsors & Collaborators

  • Hartford Hospital

    lead OTHER

Principal Investigators

  • David Tolin, PhD · Hartford Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450306 on ClinicalTrials.gov